The stock went up by 0.95 per cent to close at Rs 545.65 on BSE. During the day, it gained 3.74 per cent to Rs 560.75.
On NSE, shares of the company rose 1 per cent to end at Rs 546.30.
In terms of equity volume, 12.19 lakh shares of the company were traded on BSE and over 2 crore shares changed hands on NSE during the day.
The company has received EIR from the United States Food and Drug Administration (USFDA) for the inspection conducted at the Halol facility during the period February 12-23, 2018, Sun Pharma said in a filing to BSE yesterday.
"The agency concluded that the inspection is now closed and the issues contained in the warning letter issued in December 2015 have been addressed," it added.
Sun Pharma MD Dilip Shanghvi said, "This is an important development for Sun Pharma. We remain committed to following the highest levels of quality and 24x7 cGMP compliance at all our manufacturing facilities globally.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)